USP发布卡马西平缓释片专论修订公告,新增溶出度第12、13法
USP Revision Bulletin Notice: Carbamazepine Extended-Release Tablets
USP小分子4专家委员会发布卡马西平缓释片专论修订公告,新增溶出度第12、13法,公告标注发布日为2026年9月25日、正式日期为2026年10月1日。新增方法用于容纳溶出条件或限度与现行方法不同的FDA批准药品。第12法使用YMC-Pack CN色谱柱(L10填料)验证,卡马西平典型保留时间约5分钟,该修订公告将替代现行专论。
USP 公开修订公告全文(Revision Bulletin Notice)。本页不包含另行提供的 USP-NF 专论/章节全文。 公告内 Posting Date:2026-09-25;公告内 Official Date:2026-10-01(分别保留,生效日不作发布日期)。 文件的拟修订、预期发布等阶段表述以公告原文为准。
Carbamazepine Extended-Release Tablets
Type of Posting Revision Bulletin
Posting Date 25-Sep-2026
Official Date 01-Oct-2026
Expert Committee Small Molecules 4
In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 4 Expert Committee has revised the Carbamazepine Extended-Release Tablets monograph. The purpose of this
revision is to add Dissolution Tests 12 and 13 to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s).
• Dissolution Test 12 was validated using the YMC-Pack CN brand of column with L10 packing. The typical retention time for carbamazepine is about 5 min.
The Carbamazepine Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.
Should you have any questions, please Jasmine Lawrence, Scientist IV (301-230-6363 or
来源:USP 公开修订公告 · uspnf.com